Introduction
Network-1 Technologies (NTIP) is a nano-cap patent company that has primarily focused on monetizing technology patents. I have written about NTIP before and while I am patiently waiting for my primary investment thesis to play out I have decided to do a deeper dive into the company's recent investment in ILiAD Biotechnology, a privately held, clinical stage biotechnology company dedicated to the prevention and treatment of human disease caused by Bordetella pertussis (also known as whooping cough). ILiAD's primary drug candidate is a pertussis vaccine booster named BPZE1 that is currently